Gilead Sciences Inc. (GILD)
Health Care7 articles
Price chart
Why is GILD moving today?
-0.7%GILD is -0.7% today, inside the ordinary range for a session (under 3%). Today's stories are context, not an explanation of a move this small.
What the feed can point to
- 1.Gilead (GILD) CEO O'Day Sells $2.2M in Company Stockneutralinvesting.com
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of yesterday
Gilead Sciences Inc. (GILD) overview
Gilead Sciences is a biopharmaceutical company known for its HIV and antiviral therapies.
GILD is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Gilead Sciences Inc. trades on the NasdaqGS under the ticker symbol GILD. The most recent market data puts the share price at about $156.19. That is down 0.75% on the session. At that price the company is worth roughly $193.67B.
Over the past 52 weeks, GILD has traded between $114.02 and $160.51. GILD also pays a dividend. It yields around 2.10% at the current price.
Key statistics
Source: Yahoo Finance - quote as of yesterday
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch GILD
GILD is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each GILD story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. GILD is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves GILD
- Earnings. GILD reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from GILD.
- Sector news. Health Care stocks often move together, so a rival's news can move GILD too.
- Index weight. GILD is big enough to move the S&P 500 on its own.
Market Mood
This week for GILD
1 story about Gilead Sciences Inc. in the last 7 days- Gilead (GILD) CEO O'Day Sells $2.2M in Company Stockneutralinvesting.com
Follow GILD without checking every day
One email every Monday with the week's biggest moves and the stories behind them. Free, unsubscribe anytime.
Latest GILD news
Gilead (GILD) CEO O'Day Sells $2.2M in Company Stock
Gilead Sciences (GILD) chairman and CEO Daniel O'Day has sold 27,394 shares of the company, amounting to $2.2 million. The transaction was executed on October 10, 2023, according to a filing with the Securities and Exchange Commission. O'Day still owns 321,539 shares following the sale, retaining a significant stake in the company. The sale is part of a pre-arranged trading plan. Such sales by insiders can sometimes be perceived negatively by investors, as they might indicate a lack of confidence in the company's future performance. However, when done as part of a pre-arranged plan, it often minimizes concerns about insider information influencing the decision. For investors, this sale could raise questions about management's outlook on Gilead's future stock performance. It is essential to consider this within the broader context of the company's recent performance and market conditions.
Read More: Gilead (GILD) CEO O'Day Sells $2.2M in Company Stock
Gilead Earnings Loom: Can Yeztugo Offset Acquisition Costs?
Gilead Sciences (GILD) is scheduled to report its earnings soon, prompting speculation on whether its drugs Yeztugo and Trodelvy can help balance acquisition expenses. The impact of these drugs could significantly affect Gilead's profitability in the upcoming financial period. Analysts and investors are closely monitoring the performance of these treatments given the costs involved in recent acquisitions. This data is crucial for stakeholders as it will influence Gilead's operational outlook and stock performance.
Read More: Gilead Earnings Loom: Can Yeztugo Offset Acquisition Costs?
Gilead Sciences (GILD) Stock Rating Reiterated After HIV Drug Approval
Cantor Fitzgerald has reiterated its rating on Gilead Sciences (GILD) following the approval of a new HIV drug. The approval is significant as it supports Gilead's position in the HIV treatment market. Market analysts are closely watching the impact of this approval on Gilead's stock performance and overall revenue growth. Investors should consider this reaffirmed rating when evaluating their positions in GILD, given the potential for increased sales.
Read More: Gilead Sciences (GILD) Stock Rating Reiterated After HIV Drug Approval
GILD's Trodelvy Receives EU Committee Backing for Breast Cancer
Gilead Sciences' (GILD) drug Trodelvy has received backing from the European Medicines Agency's (EMA) committee for its use in treating breast cancer. This endorsement is significant as it highlights the potential for Trodelvy to gain market authorization in the EU, which could enhance Gilead's portfolio in oncology. The move follows previous positive results from clinical trials demonstrating Trodelvy's effectiveness. Market analysts anticipate this approval may influence Gilead's stock performance positively as it opens new avenues for revenue generation.
Read More: GILD's Trodelvy Receives EU Committee Backing for Breast Cancer
Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment
Morgan Stanley has reassessed its outlook for Gilead Sciences (GILD) following the company's recent quarterly report. GILD reported revenue of $6.36 billion for the last quarter, reflecting a year-over-year decrease of 4%. The company's earnings per share (EPS) were reported at $1.58, slightly below analysts' expectations of $1.60. This reassessment by Morgan Stanley could influence investor sentiment and GILD's stock performance in the near term.
Read More: Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment
Gilead Sciences (GILD) DEF 14A Filing Details for April 21
Gilead Sciences Inc (GILD) filed its DEF 14A on April 21. This document provides details about the company's governance and executive compensation. The filing is essential for shareholders as it outlines voting procedures and important proposals for the annual meeting. Shareholders typically review such information to make informed decisions on company leadership and strategy.
Read More: Gilead Sciences (GILD) DEF 14A Filing Details for April 21
Gilead (GILD) acquires Tubulis for $5 billion investment
Gilead Sciences (GILD) has announced the acquisition of Tubulis, a company specializing in antibody-drug conjugates, for a sum of $5 billion. This acquisition reflects Gilead's strategic investment to enhance its pipeline in cancer therapies. The increasing focus on advanced treatment options in oncology could impact Gilead's market position and future earnings. The transaction is expected to strengthen Gilead's capabilities in developing targeted therapies.
Read More: Gilead (GILD) acquires Tubulis for $5 billion investmentMore Health Care stocks
Frequently asked questions
Is Gilead Sciences Inc. in the S&P 500?
Yes. Gilead Sciences Inc. trades as GILD and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is GILD in?
GILD sits in the Health Care sector of the S&P 500.
Where can I find the latest GILD news?
Right here. This page collects recent GILD news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Gilead Sciences Inc.'s stock price?
GILD last traded at about $156.19. Prices move all through the session, so this is the latest quote rather than a live one.
What is Gilead Sciences Inc.'s market cap?
GILD is worth roughly $193.67B. Market cap is the share price times the number of shares outstanding.